The negative effect of elevated Flotillin-1 on OS was revealed in patients with RCC (HR=2.12; 95%CI: 1.45-2.79, p<0.001) and LC (HR=1.61; 95%CI: 0.89-2.33, p<0.001), and a similar result was also observed in digestive system cancers (HR=1.47; 95%CI: 1.17-1.77, p<0.001) (Figure 3). This evidence concerns the gene FLOT1 and renal cell carcinoma.